MedTrace Logo

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

NCT03704454 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-10-12

No results posted yet for this study

Summary

This is a pilot study to test whether PYC can improve climacteric symptoms for women who have experienced either surgically or medically induced menopause as part of their treatment for breast or gynecologic cancers.

Conditions

  • Climacteric; Menorrhagia, Menopausal
  • Menopause

Interventions

DIETARY_SUPPLEMENT

50 mg PYC and then placebo

4 weeks on PYC, then 4 weeks on placebo

DIETARY_SUPPLEMENT

100 mg PYC and then placebo

4 weeks on PYC, then 4 weeks on placebo

DIETARY_SUPPLEMENT

Placebo and then 50 mg PYC

4 weeks on placebo, then 4 weeks on PYC

DIETARY_SUPPLEMENT

Placebo and then 100 mg PYC

4 weeks on placebo, then 4 weeks of PYC

Sponsors & Collaborators

  • Legacy Health System

    lead OTHER

Principal Investigators

  • Reza Antoszewska, NP-C · Legacy Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-09-15
Completion
2020-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03704454 on ClinicalTrials.gov